Patent intelligence · US
US 11261188
Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium c…
Patent details — US 11261188
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 1, 2022
- Expiration
- Feb 24, 2042
- Applicant
- PRAXIS PRECISION MEDICINES, INC.
- Claims
- 16
- CPC classes
- A61K, A61K31/437, A61K31/4985, A61K31/5025
Quick answer
US 11261188 (Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel) is held by PRAXIS PRECISION MEDICINES, INC.. Status: granted. Granted Mar 1, 2022. Expires Feb 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PRAXIS PRECISION MEDICINES, INC.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/437, A61K31/4985, A61K31/5025, A61K31/519, A61P
More from PRAXIS PRECISION MEDICINES, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12404297
Salts and crystal forms of GABA-A positive allosteric modulator
granted -
US 12325711
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-α]pyrazine as an ion channel modulator
granted -
US 12259378
Dynamic clamps and methods of use thereof
granted -
US 12145939
Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
granted -
US 12077502
Formulations of T-type calcium channel modulators and methods of use thereof
granted -
US 11918571
Compounds and their methods of use
granted -
US 11919836
Prodrugs of fencamfamine
granted -
US 11866439
Ion channel modulators
granted
Frequently asked questions
What is US patent 11261188?
US 11261188 (Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel) is held by PRAXIS PRECISION MEDICINES, INC.. Status: granted. Granted Mar 1, 2022. Expires Feb 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11261188?
PRAXIS PRECISION MEDICINES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 11261188 expire?
Our index shows an expiration date of Feb 24, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.